BR0211943A - Anticorpo humano recombinante, molécula de ácido nucléico isolada, célula hospedeira, método para expressar um anticorpo em uma célula hospedeira, método para produzir um anticorpo, uso de um anticorpo humano recombinante, método para diagnóstico da malária, anticorpo humano recombinante purificado, composição, processo de tratamento de uma infecção malárica, método para triar uma coleção de exibição de fago, e, anticorpo - Google Patents

Anticorpo humano recombinante, molécula de ácido nucléico isolada, célula hospedeira, método para expressar um anticorpo em uma célula hospedeira, método para produzir um anticorpo, uso de um anticorpo humano recombinante, método para diagnóstico da malária, anticorpo humano recombinante purificado, composição, processo de tratamento de uma infecção malárica, método para triar uma coleção de exibição de fago, e, anticorpo

Info

Publication number
BR0211943A
BR0211943A BR0211943-9A BR0211943A BR0211943A BR 0211943 A BR0211943 A BR 0211943A BR 0211943 A BR0211943 A BR 0211943A BR 0211943 A BR0211943 A BR 0211943A
Authority
BR
Brazil
Prior art keywords
antibody
recombinant human
host cell
human antibody
nucleic acid
Prior art date
Application number
BR0211943-9A
Other languages
English (en)
Inventor
Morten Steen Hanefeld Dziegiel
Rasmus Lundquist
Leif Kofoed Nielsen
Original Assignee
Ram Biotech Aps
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ram Biotech Aps, Pasteur Institut filed Critical Ram Biotech Aps
Publication of BR0211943A publication Critical patent/BR0211943A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C07K16/205—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

"ANTICORPO HUMANO RECOMBINANTE, MOLéCULA DE áCIDO NUCLéICO ISOLADA, CéLULA HOSPEDEIRA, MéTODO PARA EXPRESSAR UM ANTICORPO EM UMA CéLULA HOSPEDEIRA, MéTODO PARA PRODUZIR LTM ANTICORPO USO DE UM ANTICORPO HUMANO RECOMBINANTE, MéTODO PARA DIAGNóSTICO DA MALáRIA, ANTICORPO HUMANO RECOMBINANTE PURIFICADO, COMPOSIçãO, PROCESSO DE TRATAMENTO DE UMA INFECçãO MALáRICA, MéTODO PARA TRIAR UMA COLEçãO DE EXIBIçãO DE FAGO, E, ANTICORPO". A presente invenção diz respeito a um anticorpo humano recombinante que compreende uma seq³ência de anticorpo especifica para o antígeno MSP-3 de plasmodium falciparum. Em particular, a invenção diz respeito a um anticorpo humano recombinante que é específico para o antigeno MSP-3~ 19-257~. A invenção ainda diz respeito a um ácido nucléico que codifica tais anticorpos e aos usos destes anticorpos, em particular no tratamento ou profilaxia da malária.
BR0211943-9A 2001-08-16 2002-08-16 Anticorpo humano recombinante, molécula de ácido nucléico isolada, célula hospedeira, método para expressar um anticorpo em uma célula hospedeira, método para produzir um anticorpo, uso de um anticorpo humano recombinante, método para diagnóstico da malária, anticorpo humano recombinante purificado, composição, processo de tratamento de uma infecção malárica, método para triar uma coleção de exibição de fago, e, anticorpo BR0211943A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0120057A GB2378949B (en) 2001-08-16 2001-08-16 Recombinant anti-plasmodium falciparum antibodies
PCT/IB2002/003995 WO2003016354A2 (en) 2001-08-16 2002-08-16 Recombinant anti-plasmodium falciparum antibodies

Publications (1)

Publication Number Publication Date
BR0211943A true BR0211943A (pt) 2004-09-21

Family

ID=9920560

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0211943-9A BR0211943A (pt) 2001-08-16 2002-08-16 Anticorpo humano recombinante, molécula de ácido nucléico isolada, célula hospedeira, método para expressar um anticorpo em uma célula hospedeira, método para produzir um anticorpo, uso de um anticorpo humano recombinante, método para diagnóstico da malária, anticorpo humano recombinante purificado, composição, processo de tratamento de uma infecção malárica, método para triar uma coleção de exibição de fago, e, anticorpo

Country Status (9)

Country Link
US (1) US7811569B2 (pt)
EP (1) EP1417234B1 (pt)
JP (1) JP4475949B2 (pt)
AU (1) AU2002326106B2 (pt)
BR (1) BR0211943A (pt)
CA (1) CA2458890C (pt)
DK (1) DK1417234T3 (pt)
GB (1) GB2378949B (pt)
WO (1) WO2003016354A2 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2697022B1 (fr) * 1992-10-19 1994-12-16 Pasteur Institut Antigènes de Plasmodium falciparum capables d'induire des anticorps protecteurs à large spectre - Application à la vaccination.
US20030161840A1 (en) 1992-10-19 2003-08-28 Institut Pasteur Plasmodium falciparum antigens inducing protective antibodies
EP1598419A1 (en) 2003-02-28 2005-11-23 Mitsubishi Pharma Corporation Monoclonal antibody, gene encoding the same, hybridoma, medicinal composition and diagnostic reagent
CA2580589C (en) * 2006-12-19 2016-08-09 Fio Corporation Microfluidic detection system
CA2682826C (en) 2007-04-02 2013-08-13 Fio Corporation System and method of deconvolving multiplexed fluorescence spectral signals generated by quantum dot optical coding technology
CA2692259C (en) 2007-06-22 2012-07-31 Fio Corporation Systems and methods for manufacturing quantum dot-doped polymer microbeads
CA2693055C (en) * 2007-07-09 2012-02-21 Fio Corporation Systems and methods for enhancing fluorescent detection of target molecules in a test sample
BRPI0814205A2 (pt) * 2007-07-23 2015-01-27 Fio Corp Método e sistema de coleta, armazenamento, análise e permissão de acesso a dados coletados e analisados associados a indivíduos de testes biológicos e ambientais
US8551763B2 (en) * 2007-10-12 2013-10-08 Fio Corporation Flow focusing method and system for forming concentrated volumes of microbeads, and microbeads formed further thereto
KR100968848B1 (ko) * 2007-12-13 2010-07-09 주식회사 바이오랜드 삼일열 및 열대열 말라리아 젖산탈수소효소에 특이적인항체 및 이를 포함하는 열대열 말라리아와 삼일열말라리아의 중복 감염 진단 키트
WO2009155704A1 (en) 2008-06-25 2009-12-30 Fio Corporation Bio-threat alert system
RU2515209C2 (ru) 2008-08-29 2014-05-10 Эф-Ай-Оу Корпорейшн Одноразовый портативный диагностический прибор и соответствующая система и способ исследования биологических и природных образцов
WO2010081219A1 (en) 2009-01-13 2010-07-22 Fio Corporation A handheld diagnostic test device and method for use with an electronic device and a test cartridge in a rapid diagnostic test
EP2223937A1 (en) 2009-02-27 2010-09-01 Institut Pasteur Polypeptides for the prevention or treatment of malaria
MX2012006072A (es) * 2009-11-30 2012-07-23 Genentech Inc Composiciones y metodos para el diagnostico y el tratamiento de tumores.
CN102103141B (zh) * 2009-12-18 2014-04-09 中国疾病预防控制中心寄生虫病预防控制所 快速诊断疟疾及其病原体种属的免疫层析试剂盒及其制作方法
WO2014087007A1 (en) * 2012-12-06 2014-06-12 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Plasmodium falciparum neutralizing antibodies
EP3020774B1 (en) * 2014-11-14 2022-12-28 3M Innovative Properties Company Rubber-based multilayer pressure-sensitive adhesive assembly
WO2016205585A1 (en) * 2015-06-17 2016-12-22 The Johns Hopkins University Compositions and methods for detection of malaria parasite biomarkers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897354A (en) * 1986-07-28 1990-01-30 University Of Hawaii Monoclonal antibody-specific merozoite antigens
AU633698B2 (en) 1990-01-12 1993-02-04 Amgen Fremont Inc. Generation of xenogeneic antibodies
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US5824307A (en) * 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
FR2697022B1 (fr) * 1992-10-19 1994-12-16 Pasteur Institut Antigènes de Plasmodium falciparum capables d'induire des anticorps protecteurs à large spectre - Application à la vaccination.
WO1996037234A1 (en) * 1995-05-23 1996-11-28 Thomas Jefferson University Intracellular immunization
JP4638035B2 (ja) * 1998-08-28 2011-02-23 ジェネンテック， インコーポレイテッド ヒト抗−ＩＸ／ＩＸａ因子抗体
AU6266899A (en) * 1998-10-05 2000-04-26 Ludwig Institute For Cancer Research Methods for producing human tumor antigen specific antibodies
WO2001036587A2 (en) * 1999-11-15 2001-05-25 Humanbio Co., Ltd. Gene for encoding merozoite surface protein of plasmodium vivax and use thereof

Also Published As

Publication number Publication date
JP2005509410A (ja) 2005-04-14
DK1417234T3 (da) 2014-02-24
CA2458890A1 (en) 2003-02-27
WO2003016354A2 (en) 2003-02-27
EP1417234A2 (en) 2004-05-12
GB2378949A (en) 2003-02-26
JP4475949B2 (ja) 2010-06-09
CA2458890C (en) 2014-12-16
GB2378949B (en) 2005-09-07
US20050004346A1 (en) 2005-01-06
WO2003016354A3 (en) 2003-11-06
EP1417234B1 (en) 2013-12-25
US7811569B2 (en) 2010-10-12
GB0120057D0 (en) 2001-10-10
AU2002326106B2 (en) 2007-04-26

Similar Documents

Publication Publication Date Title
BR0211943A (pt) Anticorpo humano recombinante, molécula de ácido nucléico isolada, célula hospedeira, método para expressar um anticorpo em uma célula hospedeira, método para produzir um anticorpo, uso de um anticorpo humano recombinante, método para diagnóstico da malária, anticorpo humano recombinante purificado, composição, processo de tratamento de uma infecção malárica, método para triar uma coleção de exibição de fago, e, anticorpo
DK0751992T3 (da) Karendotelvækstfaktor 2
DE69609188D1 (de) Neutralisierende monoklonale antikörper gegen respiratorischen synzytialvirus
BR0211630A (pt) Anticorpo, ácido nucleico isolado, vetores de expressão recombinantes, composição farmacêutica, método de inibição da atividade de tnfsf13b em um indivìduo sofrendo de um distúrbio no qual a atividade de tnfsf13b é prejudicial, uso do dito anticorpo, e, artigo de manufatura
HUP0303753A2 (hu) Fúziós fehérjék immunogenitásának csökkentése
DE69428214T2 (de) Transformierender wachstumsfaktor alpha h1
DE69939312D1 (de) Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen
RS20120347A2 (en) ANGELS FOR OPGL
DE69632536D1 (de) Impfstoffe für das respiratorische-synzytial-virus mit nuklein säuren
DE60239763D1 (de) Knochenpolypeptid-1
Korir et al. Proteomic studies of Plasmodium knowlesi SICA variant antigens demonstrate their relationship with P. falciparum EMP1
ES2167561T3 (es) Moleculas de acido nucleico aisladas, peptidos que forman complejos con la molecula mhc hla-a2 y usos de los mismos.
HUP0105379A2 (hu) Lawsonia intracellularis elleni oltóanyag
Céspedes et al. Antigenicity and immunogenicity of a novel chimeric peptide antigen based on the P. vivax circumsporozoite protein
ATE290080T1 (de) Menschliches beta-9 chemokin
Cheng et al. Characterization of a novel merozoite surface protein of Plasmodium vivax, Pv41
YU91403A (sh) Antitela specifična za cd44v6
Kusi et al. Immunization with different Pf AMA1 alleles in sequence induces clonal imprint humoral responses that are similar to responses induced by the same alleles as a vaccine cocktail in rabbits
ATE291437T1 (de) Verwendung von botulinustoxin zur gewinnung eines produkts für die verwendung bei gelenkerkrankungen, insbesondere hüftgelenkarthrose, epicondylitis und rotatorkappenerkrankungen
AU2010241253A1 (en) Synthetic active peptide fragments
EP1279735A4 (en) POLYPEPTIDE SE36 OF ANTIGEN MALARIA PLASMODIUM, PROCESS FOR THE PURIFICATION OF SAID POLYPEPTIDE, VACCINE AND DIAGNOSTIC METHOD USING THE ANTIGEN THUS OBTAINED
KR890013181A (ko) 플라스모듐 팔시파럼(plasmodium falciparum)의 주위 포자소체 유전자로부터 유도된 재조합 단백질의 제조방법
CN101052413B (zh) 特异性组蛋白在治疗寄生虫病中的应用
Barnwell Antigens of Plasmodium vivax blood stage parasites identified by monoclonal antibodies
Arévalo-Herrera et al. Immunogenicity of full-length P. vivax rPvs48/45 protein formulations in BALB/c mice

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: RAM BIOTECH APS (DK) , RAM BIOTECH APS (DK)

B25K Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: republication

Owner name: RAM BIOTECH APS (DK)

Free format text: RETIFICACAO DO DESPACHO (25.1) - TRANSFERENCIA DEFERIDA PUBLICADO NA RPI NO 2260, DE 29/04/2014, QUANTO AO ITEM (71) - NOME DO DEPOSITANTE. ONDE SE LE: "RAM BIOTECH APS (DK) , RAM BIOTECH APS (DK)" LEIA-SE: "RAM BIOTECH APS (DK)"

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 14A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.